Development of A Comprehensive Cell-Based Transporter Assay Platform

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$406,969.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43GM086970-01
Award Id:
93818
Agency Tracking Number:
GM086970
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
OPTIVIA BIOTECHNOLOGY, INC., 115 CONSTITUTION DR, STE 7, MENLO PARK, CA, 94025
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
804420029
Principal Investigator:
DALLAS BEDNARCZYK
() -
Business Contact:
YONG HUANG
() -
yhuang@optiviabio.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Transporters are a class of more than 300 membrane proteins that regulate how nutrients and drugs enter and leave biological cells. Transporters have validated clinical significance and affect every aspect of drug ADMET (Absorption, Distribution, Metabolism, Elimination and Toxicity). Utilizing the full potentials of transporters open new possibilities of designing safer and more efficacious drugs, through improving drug bioavailability, achieving more targeted tissue di stribution and reducing adverse drug effects due to drug-drug interactions. Existing transporter assay methods are not able to address the rapidly growing demands for more transporter assays in better model systems. We have demonstrated the feasibility of using a novel transient-expression technology for setting up transporter-specific assays in polarized cell monolayers; this approach could significantly reduce time and cost for developing similar assays using conventional methods, therefore, could notably increase the utilities of transporter proteins in drug discovery and development. The Phase I project is designed to thoroughly examine this assay approach, and to develop and characterize functional assays for 10 therapeutically important transporters. O ther advanced assay setups, such as dual-transporter and knock- out/over-expression models, will also be explored during Phase I. Future Phase II project would be to scale up development efforts for building assays for significantly more transporters, and to explore other cell models, such as human primary cultures, in order to build a better transporter assay platform, for improving prediction of drug ADMET properties in the human. Public Health Relevance: Success of this project will benefit public health by facilitating discovery and development of more efficacious drugs for treating various formidable diseases, particularly CNS diseases and cancer, and by improving drug safety through reducing adverse drug effects due to unwanted tissue distribution and drug-drug interactions.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government